Skip to main content
SpringerLink
Log in

Prevention of Hepatitis C Virus Infection and Liver Cancer

  • Chapter
  • First Online:
Viruses and Human Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 217))

Abstract

Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second leading cause of cancer-related death worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stal P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R (2013) A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57(2):230–236

    Article  PubMed  CAS  Google Scholar 

  • Alkofer B, Lepennec V, Chiche L (2011) Hepatocellular cancer in the non-cirrhotic liver. J Visceral Surg 148(1):3–10

    Article  CAS  Google Scholar 

  • Alter MJ (1995) Epidemiology of hepatitis C in the West. Semin Liver Dis 15(1):5–14

    Article  PubMed  CAS  Google Scholar 

  • Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin C-W, Mensa FJ (2018) Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 16(3):417–426

    Article  PubMed  CAS  Google Scholar 

  • Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K (2019) Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol 4(1):45–51

    Article  PubMed  Google Scholar 

  • Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA (2011) A Sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 9(6):509–U145

    Article  PubMed  Google Scholar 

  • Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O’Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4(115):115ra111

    Article  CAS  Google Scholar 

  • Bartenschlager R, Penin F, Lohmann V, Andre P (2011) Assembly of infectious hepatitis C virus particles. Trends Microbiol 19(2):95–103

    Article  PubMed  CAS  Google Scholar 

  • Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffman M, Neumann-Haefelin C, Thimme R, Henneke P, Klein RS, Paranhos-Baccala G, Depla E, Liang TJ, Blum H, Baumert TF (2005) Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105(9):3605–3614

    Article  PubMed  CAS  Google Scholar 

  • Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA (2010) High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 25(7):1276–1280

    Article  PubMed  CAS  Google Scholar 

  • Baumert TF, Ito S, Wong DT, Liang TJ (1998) Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72(5):3827–3836

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, Greenberg HB, Ito S, Liang TJ (1999) Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 117(6):1397–1407

    Article  PubMed  CAS  Google Scholar 

  • Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P (2013) Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 57(4):1303–1313

    Article  PubMed  CAS  Google Scholar 

  • Beaumont E, Roch E, Chopin L, Roingeard P (2016) Hepatitis C virus E1 and E2 proteins used as separate immunogens induce neutralizing antibodies with additive properties. PLoS ONE 11(3):e0151626

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Beaumont E, Roingeard P (2015) Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine. Vaccine 33(8):973–976

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Beinhardt S, Al-Zoairy R, Kozbial K, Stattermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H (2018) Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver International 38(7):1188–1197

    Article  PubMed  CAS  Google Scholar 

  • Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL (2000) HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32(4):673–684

    Article  PubMed  CAS  Google Scholar 

  • Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Lilly SL, Holdsworth R, Bowden SD, Jackson DC, Hellard M, Torresi J, McCluskey J (2009) TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. Immunol Cell Biol 87(6):464–472

    Article  PubMed  CAS  Google Scholar 

  • Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, Waked I, Alavian SM, Lee MH, Negro F, Abaalkhail F, Abdou A, Abdulla M, Abou Rached A, Aho I, Akarca U, Al Ghazzawi I, Al Kaabi S, Al Lawati F, Al Namaani K, Al Serkal Y, Al-Busafi SA, Al-Dabal L, Aleman S, Alghamdi AS, Aljumah AA, Al-Romaihi HE, Andersson MI, Arendt V, Arkkila P, Assiri AM, Baatarkhuu O, Bane A, Ben-Ari Z, Bergin C, Bessone F, Bihl F, Bizri AR, Blachier M, Blasco AJ, Mello CEB, Bruggmann P, Brunton CR, Calinas F, Chan HLY, Chaudhry A, Cheinquer H, Chen CJ, Chien RN, Choi MS, Christensen PB, Chuang WL, Chulanov V, Cisneros L, Clausen MR, Cramp ME, Craxi A, Croes EA, Dalgard O, Daruich JR, de Ledinghen V, Dore GJ, El-Sayed MH, Ergor G, Esmat G, Estes C, Falconer K, Farag E, Ferraz MLG, Ferreira PR, Flisiak R, Frankova S, Gamkrelidze I, Gane E, Garcia-Samaniego J, Khan AG, Gountas I, Goldis A, Gottfredsson M, Grebely J, Gschwantler M, Pessoa MG, Gunter J, Hajarizadeh B, Hajelssedig O, Hamid S, Hamoudi W, Hatzakis A, Himatt SM, Hofer H, Hrstic I, Hui YT, Hunyady B, Idilman R, Jafri W, Jahis R, Janjua NZ, Jarcuska P, Jeruma A, Jonasson JG, Kamel Y, Kao JH, Kaymakoglu S, Kershenobich D, Khamis J, Kim YS, Kondili L, Koutoubi Z, Krajden M, Krarup H, Lai MS, Laleman W, Lao WC, Lavanchy D, Lazaro P, Leleu H, Lesi O, Lesmana LA, Li M, Liakina V, Lim YS, Luksic B, Mahomed A, Maimets M, Makara M, Malu AO, Marinho RT, Marotta P, Mauss S, Memon MS, Correa MCM, Mendez-Sanchez N, Merat S, Metwally AM, Mohamed R, Moreno C, Mourad FH, Mullhaupt B, Murphy K, Nde H, Njouom R, Nonkovic D, Norris S, Obekpa S, Oguche S, Olafsson S, Oltman M, Omede O, Omuemu C, Opare-Sem O, Ovrehus ALH, Owusu-Ofori S, Oyunsuren TS, Papatheodoridis G, Pasini K, Peltekian KM, Phillips RO, Pimenov N, Poustchi H, Prabdial-Sing N, Qureshi H, Ramji A, Razavi-Shearer D, Razavi-Shearer K, Redae B, Reesink HW, Ridruejo E, Robbins S, Roberts LR, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Safadi R, Sagalova O, Salupere R, Sanai FM, Avila JFS, Saraswat V, Sarmento-Castro R, Sarrazin C, Schmelzer JD, Schreter I, Seguin-Devaux C, Shah SR, Sharara AI, Sharma M, Shevaldin A, Shiha GE, Sievert W, Sonderup M, Souliotis K, Speiciene D, Sperl J, Starkel P, Stauber RE, Stedman C, Struck D, Su TH, Sypsa V, Tan SS, Tanaka J, Thompson AJ, Tolmane I, Tomasiewicz K, Valantinas J, Van Damme P, van der Meer AJ, van Thiel I, Van Vlierberghe H, Vince A, Vogel W, Wedemeyer H, Weis N, Wong VWS, Yaghi C, Yosry A, Yuen MF, Yunihastuti E, Yusuf A, Zuckerman E, Razavi H, Polaris Observ HCVC (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2(3):161–176

    Article  Google Scholar 

  • Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, Ledinghen VD, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S, Polaris and P.-Investigators (2017) Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. New Engl J Med 376(22):2134–2146

    Article  PubMed  CAS  Google Scholar 

  • Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londono MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W (2017) Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2(8):585–594

    Article  PubMed  Google Scholar 

  • Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80(6):1197–1213

    Article  PubMed  CAS  Google Scholar 

  • Buhler S, Bartenschlager R (2012) New targets for antiviral therapy of chronic hepatitis C. Liver Int: Off J Int Assoc Study Liver 32(Suppl 1):9–16

    Article  CAS  Google Scholar 

  • Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, Silvestry M, Kuhn RJ, Rice CM (2013) Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci USA 110(23):9505–9510

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen SL, Morgan TR (2006) The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3(2):47–52

    Article  PubMed  PubMed Central  Google Scholar 

  • Cheng G, Yu M, Peng B, Lee YJ, Trejo-Martin A, Gong R, Bush C, Worth A, Nash M, Chan K, Yang H, Beran R, Tian Y, Perry J, Taylor J, Yang C, Paulson M, Delaney W, Link JO (2013) GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. J Hepatol 58:S484–S485

    Article  Google Scholar 

  • Chevaliez S, Pawlotsky J-M (2007) Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol 13(17):2461–2466

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX (2016) Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 122(22):3430–3446

    Article  PubMed  Google Scholar 

  • Christiansen D, Earnest-Silveira L, Chua B, Boo I, Drummer HE, Grubor-Bauk B, Gowans EJ, Jackson DC, Torresi J (2018a) Antibody responses to a quadrivalent hepatitis C viral-like particle vaccine adjuvanted with toll-like receptor 2 agonists. Viral Immunol 31(4):338–343

    Article  PubMed  CAS  Google Scholar 

  • Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J (2018b) Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. Sci Rep 8(1):6483

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DDK, Boo I, Ramsland R, Vincan E, Drummer HE, Gowans EJ, Torresi J (2019) Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Scientific Reports 9(1):1–3

    Article  CAS  Google Scholar 

  • Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R, Torresi J, Jackson DC (2012) Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS ONE 7(10):e47492

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Chung RT, Davis GL, Jensen DM, Masur H, Saag MS, Thomas DL, Aronsohn AI, Charlton MR, Feld JJ, Fontana RJ, Ghany MG, Godofsky EW, Graham CS, Kim AY, Kiser JJ, Kottilil S, Marks KM, Martin P, Mitruka K, Morgan TR, Naggie S, Raymond D, Reau NS, Schooley RT, Sherman KE, Sulkowski MS, Vargas HE, Ward JW, Wyles DL, Panel AIHG (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62(3):932–954

    Google Scholar 

  • Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, Huang Q, Kargman S, Kozlowski J, Liu R, McCauley JA, Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H, Zhong B, Olsen DB, Ludmerer SW (2013) Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Chem Med Chem 8(12):1930–1940

    Article  PubMed  CAS  Google Scholar 

  • Collett S, Torresi J, Earnest-Silveira L, Christiansen D, Elbourne A, Ramsland PA (2019) Probing and pressing surfaces of hepatitis C virus-like particles. J Colloid Interface Sci 545:259–268

    Article  PubMed  CAS  Google Scholar 

  • Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F (2014) Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J Infect 68(1):1–20

    Article  PubMed  Google Scholar 

  • Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S (2016) Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65(4):727–733

    Article  PubMed  CAS  Google Scholar 

  • Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M, Investigators A- (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373(27):2618–2628

    Article  PubMed  CAS  Google Scholar 

  • Desjardins D, Huret C, Dalba C, Kreppel F, Kochanek S, Cosset FL, Tangy F, Klatzmann D, Bellier B (2009) Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med 11(4):313–325

    Article  PubMed  CAS  Google Scholar 

  • Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P (2001) The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatol (Baltimore, Md) 34(6):1193–1199

    Google Scholar 

  • Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G (2002) Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155(4):323–331

    Article  PubMed  CAS  Google Scholar 

  • Donato MF, Invernizzi F, Rossi G, Iavarone M (2017) Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence. J Hepatol 67(6):1355–1356

    Article  PubMed  Google Scholar 

  • Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A (2011) A genetically humanized mouse model for hepatitis C virus infection. Nature 474(7350):208–211

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Earnest-Silveira L, Christiansen D, Herrmann S, Ralph SA, Das S, Gowans EJ, Torresi J (2016a) Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine. J Virol Methods 236:87–92

    Article  PubMed  CAS  Google Scholar 

  • Earnest-Silveira L, Chua B, Chin R, Christiansen D, Johnson D, Herrmann S, Ralph SA, Vercauteren K, Mesalam A, Meuleman P, Das S, Boo I, Drummer H, Bock CT, Gowans EJ, Jackson DC, Torresi J (2016b) Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line. J Gener Virol 97(8):1865–1876

    Article  CAS  Google Scholar 

  • El-Serag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the united states: where are we? where do we go? Hepatology 60(5):1767–1775

    Article  PubMed  Google Scholar 

  • Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ (2007) Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 104(20):8427–8432

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Ende AR, Kim NH, Yeh MM, Harper J, Landis CS (2015) Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 9:164

    Article  PubMed  PubMed Central  Google Scholar 

  • Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF (2016) Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines 15(12):1535–1544

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HLY, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, Investigators A- (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373(27):2599–2607

    Article  PubMed  CAS  Google Scholar 

  • Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E, Lahm A, Luzzago A, Vitelli A, Colloca S, Cortese R, Nicosia A (2006) A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12(2):190–197

    Article  PubMed  CAS  Google Scholar 

  • Forns X, Bukh J (1999) The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 3(4):693–716, vii

    Google Scholar 

  • Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AYM, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M (2015) Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 63(3):564–572

    Article  PubMed  CAS  Google Scholar 

  • Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin C-W, Kort JJ, Mensa FJ (2017) Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17(10):1062–1068

    Article  PubMed  CAS  Google Scholar 

  • Foster GR, Afdhal N, Roberts SK, Braeu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourliere M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CAM, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M, Astral and A.-. Investigators (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New Engl J Med 373(27):2608–2617

    Article  PubMed  CAS  Google Scholar 

  • Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB (2010) Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28(38):6367–6373

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377(15):1448–1455

    Article  PubMed  CAS  Google Scholar 

  • Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chene I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3(94):94ra71

    Google Scholar 

  • Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, Chisari FV (2010) Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 84(21):10999–11009

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 109(16):6205–6210

    Article  PubMed  PubMed Central  Google Scholar 

  • Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57

    Article  PubMed  Google Scholar 

  • Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645):659–662

    Article  PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, P. I. S. Group (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 140(5):346–355

    Google Scholar 

  • Hagan H, Pouget ER, Des Jarlais DC (2011) A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 204(1):74–83

    Article  PubMed  PubMed Central  Google Scholar 

  • Hahn JA, Wylie D, Dill J, Sanchez MS, Lloyd-Smith JO, Page-Shafer K, Getz WM (2009) Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 1(1):47–57

    Article  PubMed  PubMed Central  Google Scholar 

  • Haqshenas G, Dong X, Netter H, Torresi J, Gowans EJ (2007) A chimeric GB virus B encoding the hepatitis C virus hypervariable region 1 is infectious in vivo. J Gen Virol 88(Pt 3):895–902

    Article  PubMed  CAS  Google Scholar 

  • Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L (2018) A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection. Front Immunol 9:3175

    Article  PubMed  CAS  Google Scholar 

  • Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O (2000) Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology (Baltimore, Md) 32(5):958–961

    Google Scholar 

  • Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe J-J, Zarski J-P, Marcellin P, Riachi G, Bernard P-H, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky J-M, Pol S, Carrat F, Bronowicki J-P, Grp CS (2014) Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147(1):132–U235

    Article  PubMed  CAS  Google Scholar 

  • Hino O, Kajino K, Umeda T, Arakawa Y (2002) Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 37(11):883–887

    Article  PubMed  CAS  Google Scholar 

  • Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ (2011) Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 29(27):3643–3650

    Article  PubMed  PubMed Central  Google Scholar 

  • Huret C, Desjardins D, Miyalou M, Levacher B, Amadoudji Zin M, Bonduelle O, Combadiere B, Dalba C, Klatzmann D, Bellier B (2013) Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine 31(11):1540–1547

    Article  PubMed  CAS  Google Scholar 

  • Ioannou GN, Green PK, Berry K (2018) HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 68(1):25–32

    Article  Google Scholar 

  • Ishido S, Hotta H (1998) Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett 438(3):258–262

    Article  PubMed  CAS  Google Scholar 

  • Ishikawa T, Higuchi K, Kubota T, Seki K-I, Honma T, Yoshida T, Kamimura T (2012) Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 59(114):529–532

    PubMed  CAS  Google Scholar 

  • Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, Team AS (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405–2416

    Article  PubMed  CAS  Google Scholar 

  • Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, Liang TJ (2004) Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 78(13):6995–7003

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao YM, El-Serag HB (2017) Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153(4):996

    Article  PubMed  CAS  Google Scholar 

  • Kanwal F, Kramer JR, Ilyas J, Duan ZG, El-Serag HB (2014) HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US veterans with HCV. Hepatology 60(1):98–105

    Article  PubMed  CAS  Google Scholar 

  • Kao CF, Chen SY, Chen JY, Lee YHW (2004) Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 23(14):2472–2483

    Article  PubMed  CAS  Google Scholar 

  • Keck Z, Op De Beeck A, Hadlock KG, Xia J, Li T-K, Dubuisson J, Foung SK (2004) Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct propertires and biological functions. J Virol 78(17):9224–9232

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK (2008) Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82(12):6061–6066

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK (2011) Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol 85(20):10451–10463

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK (2016) Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology 64(6):1922–1933

    Article  PubMed  CAS  Google Scholar 

  • Kiyosawa K, Akahane Y, Nagata A, Furuta S (1984) Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 79(10):777–781

    PubMed  CAS  Google Scholar 

  • Kohli V, Singhal A, Elliott L, Jalil S (2012) Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transp Int: Off J Eur Soc Organ Transp 25(2):192–200

    Article  CAS  Google Scholar 

  • Kruse RL, Kramer JR, Tyson GL, Duan ZG, Chen L, El-Serag HB, Kanwal F (2014) Clinical outcomes of hepatitis B virus coinfection in a united states cohort of hepatitis C virus-infected patients. Hepatology 60(6):1871–1878

    Article  PubMed  Google Scholar 

  • Kumar A, Das S, Mullick R, Lahiri P, Tatineni R, Goswami D, Bhat P, Torresi J, Gowans EJ, Karande AA (2016) Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: a novel VLP prime-adenovirus boost strategy. Vaccine 34(8):1115–1125

    Article  PubMed  CAS  Google Scholar 

  • Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, Tamakoshi A, Grp JS (2005) Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 93(5):607–610

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B (2017) Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152(1):164

    Article  PubMed  CAS  Google Scholar 

  • Lafaro KJ, Demirjian AN, Pawlik TM (2015) Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 24(1):1

    Article  PubMed  Google Scholar 

  • Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, Wang YJ, Kato N, Omata M, Chang FY, Lee SD (2002) HCVNS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 21(31):4801–4811

    Article  PubMed  CAS  Google Scholar 

  • Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P (2004) High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127(3):924–936

    Article  PubMed  CAS  Google Scholar 

  • Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M (2013) A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS ONE 8(3):e59776

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AYM, Wahl J, Robertson M, Barr E, Haber B (2015) Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385(9973):1075–1086

    Article  PubMed  CAS  Google Scholar 

  • Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ (2001) Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34(2):417–423

    Article  PubMed  CAS  Google Scholar 

  • Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191(9):1499–1512

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lewis S, Roayaie S, Ward SC, Shyknevsky I, Jibara G, Taouli B (2013) Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. Am J Roentgenol 200(6):W610–W616

    Article  Google Scholar 

  • Li X, Hui A-M, Sun L, Hasegawa K, Torzilli G, Minagawa M, Takayama T, Makuuchi M (2004) p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 10(22):7484–7489

    Article  CAS  Google Scholar 

  • Liver, EAS (2018). EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461–511

    Google Scholar 

  • Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, H.-C. T. Group (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136(1):138–148

    Article  PubMed  CAS  Google Scholar 

  • Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H, Rusyn I (2007) Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 14(3):1182–1190

    Article  PubMed  Google Scholar 

  • Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S (1997) Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127(10):875–881

    Article  PubMed  CAS  Google Scholar 

  • Martinez-Donato G, Amador-Canizares Y, Alvarez-Lajonchere L, Guerra I, Perez A, Dubuisson J, Wychowsk C, Musacchio A, Aguilar D, Duenas-Carrera S (2014) Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation. Vaccine 32(15):1720–1726

    Article  PubMed  CAS  Google Scholar 

  • Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O (2012) Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol 27(2):291–299

    Article  PubMed  CAS  Google Scholar 

  • Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, Kottilil S (2016) Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepatitis 23(7):496–505

    Article  CAS  Google Scholar 

  • Mendenhall CL, Seeff L, Diehl AM, Ghosn SJ, French SW, Gartside PS, Rouster SD, Buskell-Bales Z, Grossman CJ, Roselle GA (1991) Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology (Baltimore, Md) 14(4 Pt 1):581–589

    Google Scholar 

  • Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77–87

    Article  PubMed  Google Scholar 

  • Midgard H, Bjoro B, Maeland A, Konopski Z, Kileng H, Damas JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O (2016) Hepatitis C reinfection after sustained virological response. J Hepatol 64(5):1020–1026

    Article  PubMed  Google Scholar 

  • Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP (2011) Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol 186(4):2355–2364

    Article  PubMed  CAS  Google Scholar 

  • Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y (2013) Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma a meta-analysis of observational studies. Ann Int Med 158(5):329

    Article  PubMed  Google Scholar 

  • Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4(9):1065–1067

    Article  PubMed  CAS  Google Scholar 

  • Munakata T, Nakamura M, Liang YQ, Li K, Lemon SM (2005) Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 102(50):18159–18164

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A 100(11):6753–6758

    Google Scholar 

  • Nault JC, Colombo M (2016) Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol 65(4):663–665

    Article  PubMed  Google Scholar 

  • Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ (2001) Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 75(5):2130–2141

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Netter HJ, Woo WP, Tindle R, Macfarlan RI, Gowans EJ (2003) Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine. Vaccine 21(21–22):2692–2697

    Article  PubMed  CAS  Google Scholar 

  • Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C (2017). In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrobial Agents Chemotherapy 61(5)

    Google Scholar 

  • Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang L-J, Or YS, Kempf D, Pilot-Matias T, Collins C (2018) In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrobial Agents Chemotherapy 62(1)

    Google Scholar 

  • Ng V, Saab S (2011) Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9(11):923–930

    Article  PubMed  Google Scholar 

  • Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC (2014) Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 59(6):2140–2151

    Article  PubMed  CAS  Google Scholar 

  • Park CY, Choi SH, Kang SM, Kang JI, Ahn BY, Kim H, Jung G, Choi KY, Hwang SB (2009) Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 51(5):853–864

    Article  PubMed  CAS  Google Scholar 

  • Patel K, Muir AJ, McHutchison JG (2006) Diagnosis and treatment of chronic hepatitis C infection. BMJ (Clin Res Ed) 332(7548):1013–1017

    Article  Google Scholar 

  • Patient R, Hourioux C, Vaudin P, Pages JC, Roingeard P (2009) Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. New Biotechnol 25(4):226–234

    Article  CAS  Google Scholar 

  • Pawlotsky JM (2016) Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151(1):70–86

    Article  PubMed  CAS  Google Scholar 

  • Peng L, Liang DY, Tong WY, Li JH, Yuan ZH (2010) Hepatitis C virus NS5A Activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 285(27):20870–20881

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset F-L, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 104(14):6025–6030

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA (2016) International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer 139(7):1534–1545

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Poordad F, Dieterich D (2012) Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepatitis 19(7):449–464

    Article  CAS  Google Scholar 

  • Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P, Investigators S (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195–1206

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin C-W, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ (2018) Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 67(4):1253–1260

    Article  PubMed  CAS  Google Scholar 

  • Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349(9055):825–832

    Article  PubMed  CAS  Google Scholar 

  • Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C, Grp H (2007) Long-term follow-up of the hepatitis CHENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepatitis 14(8):556–563

    Article  CAS  Google Scholar 

  • Pyrsopoulos N, Trilianos P, Lingiah VA, Fung P, Punnoose M (2018) The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Eur J Gastroenterol Hepatol 30(7):761–765

    Article  PubMed  CAS  Google Scholar 

  • Qiu W, Wang XW, Leibowitz B, Yang WC, Zhang L, Yu J (2011) PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology 54(4):1249–1258

    Article  PubMed  CAS  Google Scholar 

  • Raimondi S, Bruno S, Mondelli MU, Maisonneuve P (2009) Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 50(6):1142–1154

    Article  PubMed  CAS  Google Scholar 

  • Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, Singal AK (2017) Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 152(4):911–912

    Article  PubMed  Google Scholar 

  • Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M (2007) Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 91(2–3):228–235

    Article  PubMed  Google Scholar 

  • Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, Diaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J (2016) Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65(4):719–726

    Article  PubMed  CAS  Google Scholar 

  • Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB (2011) Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Diges Liver Dis 43(1):66–72

    Article  Google Scholar 

  • Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M (2015) Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2(8):e319–e327

    Article  PubMed  Google Scholar 

  • Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londono MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386(10003):1537–1545

    Article  PubMed  CAS  Google Scholar 

  • Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M (2013) High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS ONE 8(11):e80216

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, Aneja J, Reyor LL, Allen TM, Lohse AW, McGovern B, Chung RT, Kwok WW, Kim AY, Lauer GM (2012) Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 209(1) 61–75

    Google Scholar 

  • Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M (2015) The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med 13:198

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R (1998) Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (Baltimore, Md) 27(5):1435–1440

    Google Scholar 

  • Shi J, Zhu L, Liu S, Xie WF (2005) A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 92(3):607–612

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Simmons B, Saleem J, Hill A, Riley RD, Cooke GS (2016) Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62(6):683–694

    Article  PubMed  PubMed Central  Google Scholar 

  • Singal AK, Freeman DH, Anand BS (2010) Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32(7):851–858

    Article  PubMed  CAS  Google Scholar 

  • Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, Rosen HR (2006) Differential antigenic hierarchy associated with spontaneous Recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis 194:454–463

    Article  PubMed  Google Scholar 

  • Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang H-R, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HMM, Niu C, Otto MJ, Furman PA (2010) Discovery of a beta-D-2′-Deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53(19):7202–7218

    Article  PubMed  CAS  Google Scholar 

  • Steinmann D, Barth H, Gissler B, Schurmann P, Adah MI, Gerlach JT, Pape GR, Depla E, Jacobs D, Maertens G, Patel AH, Inchauspe G, Liang TJ, Blum HE, Baumert TF (2004) Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol 78(17):9030–9040

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P (2016) The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals? PLoS ONE 11(5):e0156213

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, DiMuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56(8):4161–4167

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sun C-A, Wu D-M, Lin C-C, Lu S-N, You S-L, Wang L-Y, Wu M-H, Chen C-J (2003) Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 157(8):674–682

    Article  PubMed  Google Scholar 

  • Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E (2014) A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science translational medicine 6(261):261ra153

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Kataoka S, Hashinokuchi S (2017) Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol 32(12):1982–1988

    Article  PubMed  CAS  Google Scholar 

  • Taylor JG, Appleby T, Barauskas O, Chen X, Dvory-Sobol H, Gong R, Lee J, Nejati E, Schultz B, Wang Y, Yang C, Yu M, Zipfel S, Chan K (2015) Preclinical profile of the PAN-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol 62:S681–S681

    Article  Google Scholar 

  • Tholey DM, Ahn J (2015) Impact of hepatitis C virus infection on hepatocellular carcinoma. Gastroenterol Clin North Am 44(4):761

    Google Scholar 

  • Thomas H, Foster G, Platis D (2003) Mechanisms of action of interferon and nucleoside analogues. J Hepatol 39(Suppl 1):S93–S98

    Article  PubMed  CAS  Google Scholar 

  • Tsai P-C, Huang C-F, Yu M-L (2017) Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. J Hepatol 66(2):464

    Article  PubMed  Google Scholar 

  • Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T (1993) Risk-factors for hepatocellular-carcinoma among patients with chronic liver-disease. N Engl J Med 328(25):1797–1801

    Article  PubMed  CAS  Google Scholar 

  • van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HLA (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama-Journal of the American Medical Association 308(24):2584–2593

    Article  Google Scholar 

  • Vermehren J, Park JS, Jacobson I, Zeuzem S (2018) Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol

    Google Scholar 

  • Vietheer PT, Boo I, Drummer HE, Netter HJ (2007) Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther 12(4):477–487

    Article  PubMed  CAS  Google Scholar 

  • Wakai K, Kurozawa Y, Shibata A, Fujita Y, Kotani K, Ogimoto I, Naito M, Nishio K, Suzuki H, Yoshimura T, Tamakoshi A, Grp JS (2007) Liver cancer risk, coffee, and hepatitis C virus infection: a nested case-control study in Japan. Br J Cancer 97(3):426–428

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang C, Ji D, Chen J, Shao Q, Li B, Liu JL, Wu V, Wong A, Wang YD, Zhang XY, Lu L, Wong C, Tsang S, Zhang Z, Sun J, Hou JL, Chen GF, Lau G (2017) Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 15(1):132–136

    Article  PubMed  Google Scholar 

  • Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ (2017) Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 67(6):1204–1212

    Article  PubMed  CAS  Google Scholar 

  • Westbrook RH, Dusheiko G (2014) Natural history of hepatitis C. J Hepatol 61:S58–S68

    Article  PubMed  Google Scholar 

  • Wiley TE, McCarthy M, Breidi L, Layden TJ (1998) Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology (Baltimore, Md.) 28(3):805–809

    Google Scholar 

  • Woo WP, Doan T, Herd KA, Netter HJ, Tindle RW (2006) Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol 80(8):3975–3984

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin C-W, Pilot-Matias T, Krishnan P, Mensa FJ (2017) Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology (Baltimore, Md.)

    Google Scholar 

  • Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD (2016) Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 65(4):859–860

    Article  PubMed  Google Scholar 

  • Yu G, Chi XM, Wu RH, Wang XM, Gao XZ, Kong F, Feng XW, Gao YD, Huang XX, Jin JL, Qi Y, Tu ZK, Sun B, Zhong J, Pan Y, Niu JQ (2015) Replication inhibition of hepatitis B virus and hepatitis C virus in co-infected patients in chinese population. Plos One 10(9)

    Google Scholar 

  • Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourliere M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ (2018) Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378(4):354–369

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan SY, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR (2015) Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection a randomized trial. Ann Intern Med 163(1):1–13

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Austin Hospital, Heidelberg, Victoria, 3084, Australia

    E. J. Lim

  2. Department of Medicine, The University of Melbourne, Austin Hospital, Heidelberg, Victoria, 3084, Australia

    E. J. Lim

  3. Department of Microbiology and Immunology, The University of Melbourne, Parkville, VIC, Australia

    J. Torresi

Authors
  1. E. J. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Torresi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Torresi .

Editor information

Editors and Affiliations

  1. School of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    T.-C. Wu

  2. Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

    Mei-Hwei Chang

  3. Molecular Virology Section, Laboratory of Mole, National Institute of Allergy and Infect, Bethesda, MD, USA

    Kuan-Teh Jeang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lim, E.J., Torresi, J. (2021). Prevention of Hepatitis C Virus Infection and Liver Cancer. In: Wu, TC., Chang, MH., Jeang, KT. (eds) Viruses and Human Cancer. Recent Results in Cancer Research, vol 217. Springer, Cham. https://doi.org/10.1007/978-3-030-57362-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-57362-1_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-57361-4

  • Online ISBN: 978-3-030-57362-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation